Ustekinumab effective in treating psoriasis
Sunday, May 18th, 2008Experimental drug Ustekinumab by Johnson & Johnson has shown to be effective in the treatment of moderate to severe cases of psoriasis. For more information, go to CNNMoney.
Experimental drug Ustekinumab by Johnson & Johnson has shown to be effective in the treatment of moderate to severe cases of psoriasis. For more information, go to CNNMoney.
With Spring here, and summer around the corner, those of us afflicted with Psoriasis can’t help but be excited. Don’t know what I’m talking about? It’s a fact that the sunlight, and associated heat and warmer weather, positively affect the symptoms of Psoriasis. There are a variety of reasons for this phenomenon, which include the sunlight on the scalp and other parts of the body from being outside more, to the higher humidity decreasing the overall symptoms, or dryness of the skin. Anyway, my point is only to be excited about this time of year, as your overall discomfort should decrease in the coming months.
More on Psoriasis symptoms
More on My Psoriasis, and how I eliminated my Psoriasis Symptoms
A team of researchers at Wyeth Research may have found the molecule that triggers psoriasis. By injecting mice with antibodies that neutralize the IL-22 molecule they were able to prevent the development of psoriasis-like lesions. Similarly, by injecting IL-22 into the skin of normal mice they found that it triggered the development of skin lesions. For more on this research, go to U.S. News & World Report.
A british and american research team has found that sufferers of severe psoriasis have a life expectancy of 3.5 years less than those without severe psoriasis. The study notes that to put this in perspective, the risk of death is higher than those studied with severe hypertension. Mild cases of psoriasis were not found to have an increased risk of death. What does this all mean? We need a cure for psoriasis! For more information on the severe psoriasis and death study, go to WebMD.